This post was originally published on this site
U.S. stock-index futures on Monday were heading modestly lower in a week that will see the unofficial start of first-quarter earnings, headlined by some of the nation’s largest banks, including JPMorgan Chase & Co.
JPM,
and Goldman Sachs Group
GS,
Meanwhile, market participants were also weighing comments from Federal Reserve Chairman Jerome Powell, who spoke during a “60 Minutes” interview that aired on Sunday.
How are stock benchmarks performing?
-
Futures for the Dow Jones Industrial Average
YMM21,
-0.18% YM00,
-0.18%
were off 72 points to reach 33,610, a decline of 0.2%. -
S&P 500 index futures
ESM21,
-0.19% ES00,
-0.19%
gave up 8.50 points, or 0.2%, at 4,111. -
Nasdaq-100 futures
NQM21,
-0.36% NQ00,
-0.36%
declined 39.25 points at 13,790.25, a drop of 0.3%.
On Friday, the S&P 500
SPX,
booked a 2.7% weekly gain, the Dow
DJIA,
rose 2%, and the Nasdaq Composite
COMP,
logged a 3.1% weekly rise. The S&P 500 and the Dow booked their third straight weekly gain, while the Nasdaq has climbed for two weeks in a row.
What’s driving the market?
On Sunday, Powell said that the economy is going to start growing strongly in the second half of the year, but emphasized that that rebound shouldn’t lead anyone to believe that the central bank would dial up interest rates in 2021.
“I think it’s unlikely that we would raise rates anything like this year,” Powell said during the “60 minutes” interview which was taped at the Fed’s headquarters on Wednesday and aired Sunday evening.
Read: Wall Street comes to grips with a Fed that will do what it says
The Feb boss said the economy “seems to be at an inflection point,” with strong growth coming “right now” and the weakness caused by the coronavirus pandemic in the rearview mirror.
Powell’s comments come as Wall Street is positioning for the start of first-quarter corporate results, which could offer further clues about whether one of the market’s biggest fears is coming to fruition: a too-hot economy and surge in inflation that compels policy makers to substantially dial back rates and accommodative policies ahead of the Fed’s projections at around 2023.
So far, Fed officials have said they expect a rise in inflation to be transitory and have repeatedly stated that they would be focused on ensuring that the labor market makes a full recovery before considering easing policy.
Some strategists fear, however, that stock valuations remain elevated despite uncertainties that include inflation and the tax regime.
Stocks mostly ended at records last week and the Nasdaq Composite, after falling into correction in March—defined as a drop of at least 10% from a recent peak—stands less than 2% from its Feb. 12 all-time closing high. Gains for equity benchmarks have come despite concerns about out-of-control inflation and the possibility that President Joe Biden will raise the corporate tax rate to 28% from 21% to help fund his $2.4 trillion infrastructure proposal.
“The investment community is too upbeat in our opinion, not showing any concern for plausible tax increases being proposed by the Biden administration,” wrote Citigroup research analysts, Tobias Levkovich, Lorraine Schmitt and Jennifer Stahmer, in a research note dated April 7.
“Indeed, all developments are perceived as positive news. Yet, such one-sided views are not usually a good starting point,” the Citi researchers wrote.
Meanwhile, Germany was preparing new COVID-inspired legislation which would enable the eurozone’s largest economy to impose national restrictions without regional government approval. England, meanwhile, reopened pubs for outdoor drinking, and hairdressers.
Which companies are in focus?
-
Shares of Nuance Communications
NUAN,
+0.80%
were in focus on Monday after a report that Microsoft Corp.
MSFT,
+1.03%
was in advanced talks to buy the artificial-intelligence company for about $16 billion. -
Regeneron Pharmaceuticals
REGN,
-0.25%
said Monday that it would ask the Food and Drug Administration to expand the use of its antibody drug among people exposed to the virus who haven’t yet been vaccinated, suggesting a potential new preventive applications for the drug, which is already in use to treat earlier COVID-19 cases.
